Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: June 30, 2023
☐ TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to
__________
Commission File Number: 000-17363
LIFEWAY FOODS, INC.
(Exact name of registrant a s specified in
its charter)
Illinois
36-3442829
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
6431 West Oakton , Morton Grove , IL 60053
(Address of principal executive offices, zip
code)
(847) 967-1010
(Registrant’s telephone number, including
area code)
Securities registered under Section 12(b) of
the Exchange Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, No Par Value
LWAY
Nasdaq Global Market
Securities registered under Section 12(g) of
the Exchange Act:
None
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”,
and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)
Large accelerated Filer ☐
Accelerated Filer ☐
Non-accelerated Filer ☒
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Number of shares of Common Stock, no par value,
outstanding as of Aug 10, 2023: 14,672,717 .
TABLE OF CONTENTS
PART I – FINANCIAL INFORMATION
Item 1.
Financial Statements.
3
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
20
Item 3.
Quantitative and Qualitative Disclosures About Market Risk.
27
Item 4.
Controls and Procedures.
27
PART II – OTHER INFORMATION
Item 1.
Legal Proceedings.
28
Item 1A.
Risk Factors.
28
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
28
Item 3.
Defaults Upon Senior Securities.
28
Item 5.
Other Information.
28
Item 6.
Exhibits.
28
Signatures.
29
2
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
LIFEWAY FOODS, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
June 30, 2023 and December 31, 2022
(In thousands)
June 30,
2023
December 31,
(Unaudited)
2022
Current assets
Cash and cash equivalents
$ 7,449
$ 4,444
Accounts receivable, net of allowance for doubtful accounts and discounts & allowances of $ 1,390 and $ 1,820 at June 30, 2023 and December 31, 2022 respectively
11,320
11,414
Inventories, net
9,670
9,631
Prepaid expenses and other current assets
1,214
1,445
Refundable income taxes
4
44
Total current assets
29,657
26,978
Property, plant and equipment, net
21,699
20,905
Operating lease right-of-use asset
136
174
Goodwill
11,704
11,704
Intangible assets, net
7,168
7,438
Other assets
1,800
1,800
Total assets
$ 72,164
$ 68,999
Current liabilities
Current portion of note payable
$ 1,250
$ 1,250
Accounts payable
5,565
7,979
Accrued expenses
4,294
3,813
Accrued income taxes
1,024
–
Total current liabilities
12,133
13,042
Line of credit
2,777
2,777
Note payable
1,980
2,477
Operating lease liabilities
73
104
Deferred income taxes, net
3,029
3,029
Total liabilities
19,992
21,429
Commitments and contingencies (Note 9)
–
–
Stockholders’ equity
Preferred stock, no par value; 2,500 shares authorized; no shares issued or outstanding at June 30, 2023 and December 31, 2022
–
–
Common stock, no par value; 40,000 shares authorized; 17,274 shares issued; 14,656 and 14,645 outstanding at June 30, 2023 and December 31, 2022, respectively
6,509
6,509
Paid-in capital
4,167
3,624
Treasury stock, at cost
( 16,920 )
( 16,993 )
Retained earnings
58,416
54,430
Total stockholders' equity
52,172
47,570
Total liabilities and stockholders' equity
$ 72,164
$ 68,999
See accompanying notes to consolidated financial
statements
3
LIFEWAY FOODS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
For the three and six months ended June 30,
2023 and 2022
(Unaudited)
(In thousands, except per share data)
Three Months Ended
June 30,
Six Months Ended
June 30,
2023
2022
2023
2022
Net sales
$ 39,230
$ 33,491
$ 77,134
$ 67,590
Cost of goods sold
27,299
27,207
56,329
55,070
Depreciation expense
651
587
1,299
1,243
Total cost of goods sold
27,950
27,794
57,628
56,313
Gross profit
11,280
5,697
19,506
11,277
Selling expenses
2,571
2,482
6,090
5,684
General and administrative
3,808
2,839
6,943
6,131
Amortization expense
135
135
270
270
Total operating expenses
6,514
5,456
13,303
12,085
Income (loss) from operations
4,766
241
6,203
( 808 )
Other income (expense):
Interest expense
( 109 )
( 52 )
( 213 )
( 94 )
Gain on sale of property and equipment
33
–
33
–
Other (expense) income, net
( 5 )
( 4 )
–
( 5 )
Total other income (expense)
( 81 )
( 56 )
( 180 )
( 99 )
Income (loss) before provision for income taxes
4,685
185
6,023
( 907 )
Provision (benefit) for income taxes
1,529
65
2,037
( 132 )
Net income (loss)
$ 3,156
$ 120
$ 3,986
$ ( 775 )
Earnings (loss) per common share:
Basic
$ 0.22
$ 0.01
$ 0.27
$ ( 0.05 )
Diluted
$ 0.21
$ 0.01
$ 0.26
$ ( 0.05 )
Weighted average common shares:
Basic
14,654
15,466
14,649
15,450
Diluted
15,084
15,875
15,058
15,772
See accompanying notes to consolidated financial
statements
4
LIFEWAY FOODS, INC. AND SUBSIDIARIES
Consolidated Statements of Stockholders’
Equity
(Unaudited)
(In thousands)
Common Stock
Issued
In treasury
Paid-In
Retained
Total
Shares
$
Shares
$
Capital
Earnings
Equity
Balance, January 1, 2022
17,274
$ 6,509
( 1,839 )
$ ( 13,436 )
$ 2,552
$ 53,506
$ 49,131
Stock-based compensation
–
–
–
–
109
–
109
Net loss
–
–
–
–
–
( 895 )
( 895 )
Balance, March 31, 2022
17,274
$ 6,509
( 1,839 )
$ ( 13,436 )
$ 2,661
$ 52,611
$ 48,345
Issuance of common stock
in connection with stock-based compensation
–
–
38
280
( 399 )
–
( 119 )
Stock-based compensation
–
–
–
–
746
–
746
Net income
–
–
–
–
–
120
120
Balance, June 30, 2022
17,274
$ 6,509
( 1,801 )
$ ( 13,156 )
$ 3,008
$ 52,731
$ 49,092
5
LIFEWAY FOODS, INC. AND SUBSIDIARIES
Consolidated Statements of Stockholders’
Equity
(Unaudited)
(In thousands)
Common Stock
Issued
In treasury
Paid-In
Retained
Total
Shares
$
Shares
$
Capital
Earnings
Equity
Balance, January 1, 2023
17,274
$
6,509
( 2,629
)
$
( 16,993
)
$
3,624
$
54,430
$
47,570
Stock-based compensation
–
–
–
–
343
–
343
Net income
–
–
–
–
–
830
830
Balance, March 31, 2023
17,274
$
6,509
( 2,629
)
$
( 16,993
)
$
3,967
$
55,260
$
48,743
Issuance of common stock in connection with stock-based compensation
–
–
11
73
( 112
)
–
( 39
)
Stock-based compensation
–
–
–
–
312
–
312
Net income
–
–
–
–
–
3,156
3,156
Balance, June 30, 2023
17,274
$
6,509
( 2,618
)
$
( 16,920
)
$
4,167
$
58,416
$
52,172
See accompanying notes to consolidated financial
statements
6
LIFEWAY FOODS, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
Six months ended June 30,
2023
2022
Cash flows from operating activities:
Net income (loss)
$ 3,986
$ ( 775 )
Adjustments to reconcile net income (loss) to operating cash flow:
Depreciation and amortization
1,569
1,513
Stock-based compensation
655
547
Non-cash interest expense
3
3
Bad debt expense
2
–
Deferred revenue
–
( 15 )
Gain on sale of equipment
( 33 )
–
(Increase) decrease in operating assets:
Accounts receivable
91
( 424 )
Inventories
( 39 )
( 151 )
Refundable income taxes
40
( 440 )
Prepaid expenses and other current assets
232
154
Increase (decrease) in operating liabilities:
Accounts payable
( 2,526 )
246
Accrued expenses
451
( 462 )
Accrued income taxes
1,024
( 725 )
Net cash provided by (used in) operating activities
5,455
( 529 )
Cash flows from investing activities:
Purchases of property and equipment
( 1,990 )
( 1,710 )
Proceeds from sales of equipment
40
–
Net cash used in investing activities
( 1,950 )
( 1,710 )
Cash flows from financing activities:
Repayment of note payable
( 500 )
( 500 )
Net cash used in financing activities
( 500 )
( 500 )
Net increase (decrease) in cash and cash equivalents
3,005
( 2,739 )
Cash and cash equivalents at the beginning of the period
4,444
9,233
Cash and cash equivalents at the end of the period
$ 7,449
$ 6,494
Supplemental cash flow information:
Cash paid for income taxes, net
$ 973
$ 640
Cash paid for interest
$ 238
$ 88
Non-cash investing activities
Accrued purchase of property and equipment
$ 110
$ 398
Increase in right-of-use assets and operating lease obligations
$ –
$ 36
See accompanying notes to consolidated financial
statements
7
LIFEWAY FOODS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data)
Note 1 – Basis of Presentation
The accompanying unaudited consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim
financial information, and do not include certain information and footnote disclosures required for complete, audited financial statements.
In the opinion of management, these statements include all adjustments necessary for a fair presentation of the results of all interim
periods reported herein. The consolidated financial statements and related notes should be read in conjunction with the consolidated financial
statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Results
of operations for any interim period are not necessarily indicative of future or annual results.
Principles of consolidation
The consolidated financial statements include
the accounts of Lifeway Foods, Inc. and all its wholly owned subsidiaries (collectively “Lifeway” or the “Company”).
All significant intercompany accounts and transactions have been eliminated.
Note 2 – Summary of Significant Accounting
Policies
Our significant accounting policies, which are
summarized in detail in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, have not materially changed. The following
is a description of certain of our significant accounting policies.
Use of estimates
The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in preparing the
consolidated financial statements include the reserve for promotional allowances, the valuation of goodwill and intangible assets, stock-based
and incentive compensation, and deferred income taxes.
Cash and cash equivalents
Lifeway considers cash and all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents are stated at cost, which
approximates or equals fair value due to their short-term nature.
Lifeway from time to time may have bank deposits
in excess of insurance limits of the Federal Deposit Insurance Corporation. The Company places its cash and cash equivalents with high
credit quality financial institutions. Lifeway has not experienced any losses in such accounts and believes the financial risks associated
with these financial instruments are minimal.
8
Customer concentration
Sales are predominately to companies in the retail
food industry located within the United States. Two major customers accounted for approximately 23 % and 22 % of net sales for the six months
ended June 30, 2023 and 2022, respectively. Two major customers accounted for approximately 22 % of net sales for the three months ended
June 30, 2023 and 2022.
Advertising and promotional costs
Lifeway expenses advertising costs as incurred and
is reported in Selling expense in the Company’s consolidated statement of operations. Total advertising expense was $ 2,006 and $ 1,738
for the six months ended June 30, 2023 and 2022, respectively. Total advertising expense was $ 543 and $ 533 for the three months ended
June 30, 2023 and 2022, respectively.
Segments
The Company is managed as a single reportable
segment. The Chief Executive Officer, who is the Company’s Chief Operating Decision Maker (“CODM”), reviews financial
information on an aggregate basis for purposes of allocating resources and assessing financial performance, as well as for making strategic
operational decisions and managing the organization. Substantially all of Lifeway’s consolidated revenues relate to the sale of
cultured dairy products that it produces using the same processes and materials and are sold to consumers through a common network of
distributors and retailers in the United States.
Recent accounting pronouncements
Adopted
In October 2021, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-08, Business Combinations (Topic 805):
Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new guidance provides a single comprehensive
accounting model on revenue recognition for contracts with customers and requires that the acquirer in a business combination recognize
and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with
Customers). The amendments in this ASU are effective for fiscal years beginning after December 15, 2022. The Company adopted this standard
during the first quarter of 2023. The adoption did not have a material impact on the Company’s financial statements.
In March 2020, the FASB issued ASU No. 2020-04,
Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The new guidance provides
optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR
or another reference rate expected to be discontinued because of reference rate reform. The guidance will be effective prospectively as
of March 12, 2020 through December 31, 2022 and interim periods within those fiscal years. T he
ASU was effective upon issuance and allowed companies to adopt the amendments on a prospective basis through December 31, 2024.
In June 2016, the FASB issued ASU No. 2016-13,
Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, in November 2018 issued
an amendment, ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, and in November 2019 issued
two amendments, ASU 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates, and ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments – Credit Losses. The
series of new guidance amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather
than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result
in the earlier recognition of allowances for losses. The guidance should be applied on either a prospective transition or modified-retrospective
approach depending on the subtopic. The guidance is effective for annual periods beginning after December 15, 2022, including interim
periods within those fiscal years, with early adoption permitted. The Company adopted this standard during the first quarter of 2023.
The adoption did not have a material impact on the Company’s financial statements.
9
Note 3 – Inventories, net
Inventories consisted of the following:
Schedule of inventories
June 30,
2023
December 31,
2022
Ingredients
$ 2,813
$ 2,859
Packaging
3,091
3,233
Finished goods
3,766
3,539
Total inventories, net
$ 9,670
$ 9,631
Note 4 – Property, Plant and Equipment, net
Property, plant and equipment consisted of the following:
Schedule of property, plant and equipment
June 30,
2023
December 31,
2022
Land
$
1,565
$
1,565
Buildings and improvements
19,422
19,341
Machinery and equipment
32,969
32,786
Vehicles
705
640
Office equipment
1,046
979
Construction in process
2,830
1,180
58,537
56,491
Less accumulated depreciation
( 36,838
)
( 35,586
)
Total property, plant and equipment, net
$
21,699
$
20,905
Note 5 – Goodwill and Intangible Assets
Goodwill
Goodwill consisted of the following:
Schedule of goodwill
Total
Balance at December 31, 2022, before accumulated impairment loses
$ 12,948
Accumulated impairment losses
( 1,244 )
Balance at December 31, 2022
$ 11,704
Balance at June 30, 2023
$ 11,704
10
Intangible Assets
Other intangible assets, net consisted of the following:
Schedule of finite-lived intangible assets
June 30, 2023
December 31, 2022
Gross
Net
Gross
Net
Carrying
Accumulated
Carrying
Carrying
Accumulated
Carrying
Amount
Amortization
Amount
Amount
Amortization
Amount
Recipes
$
44
$
( 44
)
$
–
$
44
$
( 44
)
$
–
Customer lists and other customer related intangibles
4,529
( 4,529
)
–
4,529
( 4,529
)
–
Customer relationship
3,385
( 1,292
)
2,093
3,385
( 1,212
)
2,173
Brand names
7,948
( 2,873
)
5,075
7,948
( 2,683
)
5,265
Formula
438
( 438
)
–
438
( 438
)
–
Total intangible assets, net
$
16,344
$
( 9,176
)
$
7,168
$
16,344
$
( 8,906
)
$
7,438
Estimated amortization expense on intangible assets
for the next five years is as follows:
Schedule of estimated amortization expense on intangible assets
Year
Amortization
Six months ended December 31, 2023
$ 270
2024
$ 540
2025
$ 540
2026
$ 540
2027
$ 540
Note 6 – Accrued Expenses
Accrued expenses consisted of the following:
Schedule of accrued expenses
June 30,
2023
December 31,
2022
Payroll and incentive compensation
$ 3,237
$ 2,925
Real estate taxes
432
394
Accrued utilities
218
121
Current portion of operating lease liabilities
63
70
Other
344
303
Total accrued expenses
$ 4,294
$ 3,813
11
Note 7 – Debt
Note payable consisted of the following:
Schedule of debt
June 30,
2023
December 31,
2022
Term loan due August 18, 2026. Interest (7.10% at June 30, 2023) payable monthly.
$ 3,250
$ 3,750
Unamortized deferred financing costs
( 20 )
( 23 )
Total note payable
3,230
3,727
Less current portion
( 1,250 )
( 1,250 )
Total long-term portion
$ 1,980
$ 2,477
The scheduled maturities of the term loan, excluding deferred financing
costs, at June 30, 2023 are as follows:
Schedule of maturities of long-term debt
Six months ended December 31, 2023
$ 750
2024
1,000
2025
1,000
2026
500
Total term loan
$ 3,250
Credit Agreement
On August 18, 2021, Lifeway entered into the Fourth
Modification (the “Fourth Modification”) to the Amended and Restated Loan and Security Agreement (as amended and modified
from time to time, the “Credit Agreement” and, as amended and modified by the Fourth Modification, the “Modified Credit
Agreement”) with its existing lender and certain of its subsidiaries. The Fourth Modification amends the Credit Agreement to provide
for, among other things, a $5 million term loan by the existing lender to the borrowers to be repaid in quarterly installments of principal
and interest over a term of five years (the “Term Loan”). The termination date of the Term Loan is August 18, 2026, unless
earlier terminated. The Amended and Restated Loan and Security Agreement continues to provide Lifeway with a revolving line of credit
up to a maximum of $5 million (the “Revolving Loan”) and provides the Borrowers with an incremental facility not to exceed
$5 million (the “Incremental Facility” and together with the Revolving Loan, the “Loans”). The Termination Date
of the Revolving Loan was extended to June 30, 2025 , unless earlier terminated.
As amended, all outstanding amounts under the
revolving line of credit and term loan bear interest, at Lifeway’s election, at either the lender Base Rate (the Prime Rate minus
1.00%) or the LIBOR plus 1.95%, payable monthly in arrears. Lifeway is also required to pay a quarterly unused revolving line of credit
fee of 0.20 % and, in conjunction with the issuance of any letters of credit, a letter of credit fee of 0.20 %.
On June 26, 2023, the Company executed the Early
Opt-In Election and Related Amendment to Loan Documents (the “SOFR Election”). Under the SOFR election, the interest rate
on the Company’s outstanding borrowings after June 30, 2023, will transition from LIBOR to the Secured Overnight Financing Rate
(“SOFR”), plus 2.07%.
The Modified Credit Agreement includes customary
representations, warranties, and covenants, including financial covenants requiring the Company to maintain a fixed charge coverage ratio
of no less than 1.25 to 1.00, and a minimum working capital financial covenant, as defined, of no less than $11.25 million, in each of
the fiscal quarters ending through the expiration date. The Modified Credit Agreement continues to provide for events of default, including
failure to repay principal and interest when due and failure to perform or violation of the provisions or covenants of the agreement,
as a result of which amounts due under the Modified Credit Agreement may be accelerated. The loans and all other amounts due and owed
under the Credit Agreement and related documents are secured by substantially all of the Company’s assets.
Lifeway was in compliance with the fixed charge
coverage ratio and minimum working capital covenants at June 30, 2023.
12
Revolving Credit Facility
As of June 30, 2023, the Company had $ 2,777 outstanding
under the Revolving Credit Facility. The Company had $ 2,223 available for future borrowings under the Revolving Credit Facility as of
June 30, 2023. Lifeway’s interest rate on debt outstanding under the Revolving Credit Facility as of June 30, 2023 was 7.14 %.
Note 8 – Leases
The Company leases certain machinery and equipment
with fixed base rent payments and variable costs based on usage. Remaining lease terms for these leases range from less than one year
to five years. The Company includes lease extension options, if applicable and reasonably certain to be exercised, in the calculation
of the right-of-use asset and lease liabilities. Lifeway includes only fixed payments for lease components in the measurement of the right-of-use
asset and lease liability. Variable lease payments are those that vary because of changes in facts or circumstances occurring after the
commencement date, other than the passage of time. There are no residual value guarantees. Lifeway does not currently have leases which
meet the finance lease classification as defined under ASC 842.
Lifeway treats contracts as a lease when the contract
conveys the right to use a physically distinct asset for a period of time in exchange for consideration, it directs the use of the asset
and obtains substantially all the economic benefits of the asset.
Right-of-use assets and lease liabilities are
measured and recognized based on the present value of the future minimum lease payments over the lease term at the commencement date.
Lifeway has elected the practical expedient to combine lease and non-lease components into a single component for all of its leases. When
the Company is unable to determine an implicit interest rate, it uses its incremental borrowing rate based on the information available
at the commencement date in determining the present value of future payments for those leases. Lifeway includes options to extend or terminate
the lease in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise such options.
Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company does not record leases with an initial
term of 12 months or less on the balance sheet. Expense for these short-term leases is recorded on a straight-line basis over the lease
term. Total lease expense was $ 61 and $ 147 (including short term leases) for the six months ended June 30, 2023 and 2022, respectively.
Total lease expense was $ 30 and $ 82 (including short term leases) for the three months ended June 30, 2023 and 2022, respectively.
Future maturities of lease liabilities were as
follows:
Schedule of future maturities of lease liabilities
Year
Operating Leases
Six months ended December 31, 2023
$ 40
2024
67
2025
33
2026
10
2027
3
Thereafter
–
Total lease payments
153
Less: Interest
( 17 )
Present value of lease liabilities
$ 136
13
The weighted-average remaining lease term for its
operating leases was 2.36 years as of June 30, 2023. The weighted average discount rate of its operating leases was 11.54 % as of June
30, 2023. Cash paid for amounts included in the measurement of lease liabilities was $ 46 and $ 85 for the six months ended June 30, 2023
and 2022, respectively. Cash paid for amounts included in the measurement of lease liabilities was $ 21 and $ 42 for the three months ended
June 30, 2023 and 2022, respectively.
Note 9 – Commitments and contingencies
Litigation
Lifeway is involved in various legal proceedings,
claims, disputes, regulatory matters, audits, and proceedings arising in the ordinary course of, or incidental to the Company’s
business, including commercial disputes, product liabilities, intellectual property matters and employment-related matters.
Lifeway records provisions in the consolidated
financial statements for pending legal matters when it believes it is probable that a loss will be incurred and the amount of such loss
can be reasonably estimated. The Company evaluates, on a periodic basis, developments in legal matters that could affect the amount of
any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both
probable and estimable, it does not establish an accrued liability. Currently, none of its accruals for outstanding legal matters are
material individually or in the aggregate to its financial position and it is management’s opinion that the ultimate resolution
of these outstanding legal matters will not have a material adverse effect on its business, financial condition, results of operations,
or cash flows. However, if the Company is ultimately required to make payments in connection with an adverse outcome, it is possible that
such contingency could have a material adverse effect on the Company’s business, financial condition, results of operations or cash
flows.
Note 10 – Income taxes
Income taxes were recognized at effective rates of
33.8 % and 14.5 % for the six months ended June 30, 2023 and 2022, respectively. Income taxes were recognized at effective rates of 32.6 %
and 35.3 % for the three months ended June 30, 2023 and 2022, respectively.
The Company calculates the provision for income taxes
during interim reporting periods by applying an estimate of the annual effective tax rate for the full year, excluding unusual or infrequently
occurring discrete items, and applies that rate to income (loss) before provision for income taxes for the period.
The Company’s effective tax rate may change
from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional
mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement
of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete
income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur. The Company consistently
reflects non-deductible officer compensation expense, non-deductible compensation expense related to equity incentive awards and separate
state tax rates from period to period. Although similar items were reflected in 2023, the percentage effect is different due to the difference
in pre-tax income (loss) in 2023 compared to 2022.
Unrecognized tax benefits were $ 0 at June 30, 2023
and 2022. The Company does not expect material changes to its unrecognized tax benefits during the next twelve months.
14
Note 11 – Stock-based and Other Compensation
Omnibus Incentive Plan
In December 2015, Lifeway stockholders approved
the 2015 Omnibus Incentive Plan, which authorized the issuance of an aggregate of 3.5 million shares to satisfy awards of stock options,
stock appreciation rights, unrestricted stock, restricted stock, restricted stock units, performance shares and performance units to qualifying
employees. Under the Plan, the Board or its Audit and Corporate Governance Committee approves stock awards to executive officers and certain
senior executives, generally in the form of restricted stock or performance shares. The number of performance shares that participants
may earn depends on the extent to which the corresponding performance goals have been achieved. Stock awards generally vest over a three-year
performance or service period. At June 30, 2023, no shares remain available for award under the 2015 Omnibus Incentive Plan as it was
terminated on August 31, 2022. However, any outstanding awards under the 2015 Omnibus Incentive Plan are unaffected by the termination
of the 2015 Omnibus Incentive Plan or by the approval of the 2022 Omnibus Incentive Plan (the “2022 Plan”) as described below.
On August 31, 2022, Lifeway
stockholders approved the 2022 Plan. Under the 2022 Plan, the Compensation Committee of the Board of Directors may grant awards of various
types of compensation, including, nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted
stock units, performance shares, performance units, cash-based awards and other stock-based awards. The maximum number of shares authorized
to be awarded under the 2022 Plan is 3.25 million shares of common stock, which includes shares that remained available under the now
terminated 2015 Omnibus Incentive Plan.
Awards granted under the
2022 Plan are generally subject to a minimum vesting period of at least one year. Awards may be subject to cliff-vesting or graded-vesting
conditions, with graded vesting starting no earlier than one year after the grant date. The Plan Administrator may provide for shorter
vesting periods in an award agreement for no more than five percent of the maximum number of shares authorized for issuance under the
2022 Plan. As of June 30, 2023, 2.77 million shares remain available to award under the 2022 Plan.
Stock Options
The following table summarizes stock option activity during the six
months ended June 30, 2023:
Schedule of stock option activity
Options
Weighted
average
exercise price
Weighted
average
remaining contractual life
Aggregate
intrinsic value
Outstanding at December 31, 2022
41
$ 10.42
3.22
$ –
Granted
–
–
–
–
Exercised
–
–
–
–
Forfeited
–
–
–
–
Outstanding at June 30, 2023
41
$ 10.42
2.72
$ –
Exercisable at June 30, 2023
41
$ 10.42
2.72
$ –
15
Restricted Stock Awards
A Restricted Stock Award (“RSA”) represents
the right to receive one share of common stock in the future. RSAs have no exercise price. The grant date fair value of the awards is
determined by the Company’s closing stock price on the grant date. Lifeway expenses RSAs over the vesting period. The following
table summarizes RSA activity during the six months ended June 30, 2023.
Schedule of RSA Activity
Restricted Stock Awards
Weighted Average Grant Date Fair Value
Outstanding at December 31, 2022
164
$
5.69
Granted
58
6.88
Shares issued upon vesting
–
–
Forfeited
( 5
)
6.25
Outstanding at June 30, 2023
217
$
5.99
Vested and deferred at June 30, 2023
37
$
5.60
For the six months ended June 30,2023 and 2022 total
pre-tax stock-based compensation expense recognized in the consolidated statements of operations was $ 202 and $ 127 , respectively. For
the six months ended June 30,2023 and 2022 tax-related benefits of $ 57 and $ 35 , respectively, were also recognized. For the three months
ended June 30, 2023 and 2022 total pre-tax stock-based compensation expense recognized in the consolidated statements of operations was
$ 98 and $ 64 , respectively. For the three months ended June 30, 2023 and 2022 tax-related benefits of $ 28 and $ 17 , respectively, were also
recognized. Future compensation expense related to restricted stock awards was $ 686 as of June 30, 2023 and will be recognized on a weighted
average basis over the next 1.40 years.
Long-Term Incentive Plan Compensation
Lifeway has established long-term incentive-based
compensation programs for certain senior executives and key employees pursuant to the terms of its incentive plans.
2020 CEO Incentive Award
During the fourth quarter 2020, Lifeway awarded a
long-term equity-based incentive of $ 750 to its Chief Executive Officer (the “2020 CEO Award”) depending on Lifeways 2020
performance levels compared to the respective targets. The equity-based incentive compensation is payable in restricted stock that vests
one-third in April 2022, one-third in April 2023, and one-third in April 2024. The issuance of vested equity awards is subject to approval
under the Stock Purchase Agreement dated October 1, 1999. For the six months ended June 30, 2023 and 2022, $ 69 and $ 142 was expensed as
stock-based compensation expense in the consolidated statements of operations, respectively. For the three months ended June 30, 2023
and 2022, $ 26 and $ 57 was expensed as stock-based compensation expense in the consolidated statements of operations, respectively. As
of June 30, 2023, the total remaining unearned compensation was $ 60 , of which $ 36 will be recognized in 2023, and $ 24 in 2024, respectively,
subject to vesting.
2021 Equity Award
The 2021 long-term equity incentive plan compensation
is based on Lifeway’s achievement of adjusted EBITDA performance versus the respective target established by the Board for 2021.
Under the 2021 plan, collectively the participants earned equity-based incentive compensation of $ 1,069 based on Lifeway’s achievement
of the respective financial target. The equity-based incentive compensation is payable in restricted stock that vests one-third in April
2022, one-third in April 2023, and one-third in April 2024. For the six months ended June 30, 2023 and 2022, $ 128 and $ 278 was expensed
as stock-based compensation expense in the consolidated statements of operations, respectively. For the three months ended June 30, 2023
and 2022, $ 44 and $ 112 was expensed as stock-based compensation expense in the consolidated statements of operations, respectively. As
of June 30, 2023, the total remaining unearned compensation was $ 106 , of which $ 66 will be recognized in 2023, $ 40 in 2024, respectively,
subject to vesting.
16
2022 Equity Award
Under the 2022 long-term incentive plan, participants
can earn a specified number of target level Performance Share Units (“PSUs”) contingent upon the achievement of strategic
milestones during the three-year Measurement Period, which is fiscal year 2022 to 2024. The strategic milestones are 1) 3-year cumulative
net revenue, and 2) 3-year cumulative adjusted EBITDA. The target number of PSU awards are weighted 50% on net revenue and 50% on adjusted
EBITDA. Collectively, the participants can earn 125,066 PSUs at the target level. Participants may earn more or less than the target number
of shares based on actual results, however the minimum and maximum number of shares that can be earned are bound by minimum and maximum
thresholds of net revenue and adjusted EBITDA. The PSU awards will be earned and will vest, if at all, after the end of the three-year
measurement period based on achievement of the milestones. The PSU awards do not vest during the three-year measurement period. The PSUs
have a grant date fair value of $6.25 dollars per share. For the six months ended June 30, 2023 and 2022, $ 240 and $ 0 was expensed as
stock-based compensation expense in the consolidated statements of operations, respectively.
For the three months ended June 30, 2023 and 2022,
$ 127 and $ 0 was expensed as stock-based compensation expense in the consolidated statements of operations, respectively.
The 2022 long-term incentive plan also granted
restricted stock unit awards that contain only a service condition and vest on the passage of time in three equal installments on each
of the first three anniversaries of the August 31, 2022 grant date. The stock-based compensation expense for these awards is included
in the Restricted Stock Award section above.
2023 Equity Award
Under the 2023 long-term incentive plan, participants
can earn a specified number of target level Performance Share Units (“PSUs”) contingent upon the achievement of strategic
milestones during the three-year Measurement Period, which is fiscal year 2023 to 2025. The strategic milestones are 1) 3-year cumulative
net revenue, and 2) 3-year cumulative adjusted EBITDA. The target number of PSU awards are weighted 50% on net revenue and 50% on adjusted
EBITDA. Collectively, the participants can earn 115,622 PSUs at the target level. Participants may earn more or less than the target number
of shares based on actual results, however the minimum and maximum number of shares that can be earned are bound by minimum and maximum
thresholds of net revenue and adjusted EBITDA. The PSU awards will be earned and will vest, if at all, after the end of the three-year
measurement period based on achievement of the milestones. The PSU awards do not vest during the three-year measurement period. The PSUs
have a grant date fair value of $6.88 dollars per share. For the six months ended June 30, 2023 and 2022, $ 16 and $ 0 was expensed as stock-based
compensation expense in the consolidated statements of operations, respectively.
For the three months ended June 30, 2023 and 2022,
$ 16 and $ 0 was expensed as stock-based compensation expense in the consolidated statements of operations, respectively.
The 2023 long-term incentive plan also granted restricted
stock unit awards that contain only a service condition and vest on the passage of time in three equal installments on each of the first
three anniversaries of the June 16, 2023 grant date. The stock-based compensation expense for these awards is included in the Restricted
Stock Award section above.
17
Non-Employee Director Plan
On August 31, 2022, Lifeway
stockholders approved the 2022 Non-Employee Director Equity and Deferred Compensation Plan (the
“ 2022 Director Plan”), which authorizes the grant of restricted stock units (“RSUs”), which will vest on
such schedule as the Company, in its sole discretion, shall determine. Each non-employee director of the Company is eligible to be a participant
in the 2022 Director Plan until they no longer serve as a non-employee director. As of the date of each annual shareholder meeting, the
Company may grant each director a number of RSUs for such year and set the vesting schedule for the RSUs granted. Whether and how many
RSUs the Company will grant to directors in any year is subject to the sole discretion of the Company and shall in any event be subject
to the 2022 Director Plan’s overall share limits. The maximum aggregate number of shares of common stock that may be issued under
the 2022 Directors Plan is 500 thousand shares. As of June 30, 2023, 466 thousand shares remain available to award under the 2022 Director
Plan. The aggregate fair market value of shares underlying RSU compensation that may be issued as RSU compensation to a director in any
year shall not exceed $170. In addition to the grant of RSUs, the 2022 Director Plan also provides for the deferral by electing participants
of all or part of their cash compensation (in 10% increments) into a deferred cash account, and they may defer all or part of their cash
and/or RSU compensation (in 10% increments) into a deferred RSU account. Deferred benefits are paid in a lump sum upon the applicable
director’s departure from the Board of Directors.
Retirement Benefits
Lifeway has a defined contribution plan which is available
to substantially all full-time employees. Under the terms of the plan, the Company matches employee contributions under a prescribed formula.
For the six months ended June 30, 2023 and 2022 total contribution expense recognized in the consolidated statements of operations was
$ 258 and $ 231 , respectively. For the three months ended June 30, 2023 and 2022, total contribution expense recognized in the consolidated
statements of operations was $ 108 and $ 102 , respectively.
Note 12 - Earnings Per Share
The following table summarizes the effects of the share-based compensation
awards on the weighted average number of shares outstanding used in calculating diluted earnings (loss) per share:
Schedule of weighted average number of shares
Three Months Ended
Six Months Ended
June 30,
June 30,
2023
2022
2023
2022
(In thousands)
Weighted average common shares outstanding
14,654
15,466
14,649
15,450
Assumed exercise/vesting of equity awards
430
409
409
322
Weighted average diluted common shares outstanding
15,084
15,875
15,058
15,772
18
Note 13 – Related Party Transactions
Consulting Services
Lifeway obtained consulting services from Ludmila
Smolyansky, a member of the Company’s Board of Directors and former Chairperson of its Board of Directors. On January 4, 2022, the
Company notified Ms. Smolyansky that it was terminating the amended and restated consultancy agreement effective January 17, 2022. Service
fees earned are included in general and administrative expenses in the accompanying consolidated statements of operations and were $ 0
and $ 22 during each of the six months ended June 30, 2023 and 2022, respectively. Service fees earned are included in general and administrative
expenses in the accompanying consolidated statements of operations and were $ 0 during each of the three months ended June 30, 2023 and
2022.
Endorsement Agreement
Lifeway was also a party to an endorsement agreement,
dated as March 14, 2016, by and between the Company and Ludmila Smolyansky, a member of the Company’s Board of Directors and former
Chairperson of its Board of Directors (the “Endorsement Agreement”) under which it paid the Chairperson a royalty based on
the sale of certain Lifeway products, not to exceed $50 in any fiscal month.
On September 6, 2022, the Company entered into
an agreement (the “Termination Agreement”) with Ms. Smolyansky that terminated the Endorsement Agreement as of September 6,
2022.
Pursuant to the Termination
Agreement, the Company and Ms. Smolyansky have agreed, among other things, that (i) the Company paid Ms. Smolyansky a lump sum payment
of $400, (ii) Ms. Smolyansky will no longer have any further claims against the Company under the
Endorsement Agreement, and (iii) the Endorsement Agreement was terminated and of no further force or effect except for the provisions
thereof that expressly survive termination.
Royalties earned were $ 0 and $ 300 during each
of the six months ended June 30, 2023 and 2022, respectively. Royalties earned were $ 0 and $ 150 during each of the three months ended
June 30, 2023 and 2022, respectively.
19
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
Management’s Discussion
and Analysis of Financial Condition and Results of Operations (“MD&A”) in this Form 10-Q is provided as a supplement to,
and should be read in conjunction with, our audited consolidated financial statements, the accompanying notes, and the MD&A included
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”). Unless otherwise specified,
any description of “our”, “we”, and “us” in this MD&A refer to Lifeway Foods, Inc. and our subsidiaries.
Cautionary Statement Regarding Forward-Looking
Statements
In addition to historical information, this quarterly
report contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “from
time to time,” “intend,” “plan,” “ongoing,” “realize,” “should,” “may,”
“could," "believe," "future," "depend," "expect," "will," "result,"
"can," "remain," "assurance," "subject to," "require," "limit," "impose,"
"guarantee," "restrict," "continue," "become," "predict," "likely," "opportunities,"
"effect," "change," "predict," and "estimate,” and similar terms or terminology, or the negative
of such terms or other comparable terminology. Examples of forward-looking statements include, among others, statements we make regarding:
·
Expectations of the effect on our financial condition of claims, litigation, environmental costs, contingent liabilities and governmental and regulatory investigations and proceedings;
·
Strategy for acquisitions, customer retention, growth, product development, market position, financial results and reserves; Estimates of the amounts of sales allowances and discounts to our customers and consumers;
·
Our belief that we will maintain compliance with our loan agreements and have sufficient liquidity to fund our business operations.
Forward looking statements are based on management’s
beliefs, assumptions, estimates and observations of future events based on information available to our management at the time the statements
are made and include any statements that do not relate to any historical or current fact. These statements are not guarantees of future
performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may
differ materially from what is expressed, implied or forecast by our forward-looking statements due in part to the risks, uncertainties,
and assumptions that include:
·
Changes in the pricing of commodities;
·
The actions and decisions of our competitors and customers, including those related to price competition;
·
Our ability to successfully implement our business strategy;
·
The effects of government regulation;
·
Disruptions to our supply chain, or our manufacturing and distribution capabilities, including those due to cybersecurity threats; and
·
Such other factors as discussed throughout Part I, Item 1 “Business”; Part I, Item 1A “Risk Factors”; and Part II, Item 7 “Management's Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2022 and that are described from time to time in our filings with the SEC.
These factors are not necessarily all of the important
factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown
or unpredictable factors could also have material adverse effects on future results. The Company intends these forward-looking statements
to speak only at the date made. Except as otherwise required to be disclosed in periodic reports required to be filed by public companies
with the SEC pursuant to the SEC's rules, Lifeway has no duty to update these statements, and it undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
20
Business Overview
Lifeway was founded in 1986 by Michael Smolyansky
shortly after he and his wife, Ludmila Smolyansky, emigrated from Eastern Europe to the United States. Lifeway was the first to successfully
introduce kefir to the U.S. consumer on a commercial scale, initially catering to ethnic consumers in the Chicago, Illinois metropolitan
area.
The Company’s primary product is drinkable
kefir, a cultured dairy product. Lifeway Kefir is tart and tangy, high in protein, calcium and vitamin D. Thanks to our exclusive blend
of kefir cultures, each cup of kefir contains 12 live and active cultures and 25 to 30 billion beneficial CFU (Colony Forming Units) at
the time of manufacture.
The Company manufactures (directly or through
a co-manufacturer) and markets products under the Lifeway, Fresh Made, and GlenOaks Farms brand names, as well as under private labels
on behalf of certain customers.
The Company’s product categories are:
·
Drinkable Kefir, a cultured dairy product sold in a variety of organic and non-organic sizes, flavors, and types.
·
European-style soft cheeses, including farmer cheese, white cheese, and Sweet Kiss.
·
Cream and other, which primarily consists of cream, a byproduct of raw milk processing.
·
Drinkable Yogurt, sold in a variety of sizes and flavors.
·
ProBugs, a line of kefir products designed for children.
·
Other Dairy, which primarily consists of Fresh Made butter and sour cream.
Recent Developments
Current Macroeconomic Environment and Inflation Impact
Since 2022, we have been experiencing inflationary
and cost pressures due to volatility and disruption in the global economy which have increased our production and distribution costs.
We have begun to see some moderation of inflationary pressures and have experienced pricing declines in certain of our input costs, such
as milk. We expect inflationary pressures to persist throughout 2023, although at lower levels than experienced in 2022. In response to
these persistent inflationary and cost pressures, we instituted price increases in 2022 on many of our products. We expect that these
inflation-justified price increases will continue to help mitigate our increased costs.
We have not experienced significant supply chain
disruptions or labor supply shortages and have continued to satisfy customer and consumer demand for our products. Management continues
to proactively manage the supply and transportation of materials used to make and package our products, staffing, and transportation of
our products to customers. This proactive planning has allowed the Company to avoid disruption to its manufacturing facilities and production,
transportation, and sales and to meet the increased demand. The Company has maintained full production at all locations and does not anticipate
manufacturing or staffing disruptions in the near term.
21
Results of Operations
Three Months Ended June 30, 2023 Compared to Three Months Ended
June 30, 2022
The following table presents certain information
concerning our financial results, including information presented as a percentage of consolidated net sales:
Three Months Ended June 30,
2023
2022
$
%
$
%
Net sales
39,230
100.0%
33,491
100.0%
Cost of goods sold
27,299
69.6%
27,207
81.2%
Depreciation expense
651
1.7%
587
1.8%
Total cost of goods sold
27,950
71.3%
27,794
83.0%
Gross profit
11,280
28.7%
5,697
17.0%
Selling expenses
2,571
6.6%
2,482
7.4%
General & administrative expense
3,808
9.7%
2,839
8.5%
Amortization expense
135
0.3%
135
0.4%
Total operating expenses
6,514
16.6%
5,456
16.3%
Income from operations
4,766
12.1%
241
0.7%
Other (expense) income:
Interest expense
(109 )
(0.3% )
(52 )
(0.2% )
Gain on sales of property and equipment
33
0.1%
–
0.0%
Other (expense) income, net
(5 )
0.0%
(4 )
0.0%
Total other (expense) income
(81 )
(0.2% )
(56 )
(0.2% )
Income before provision for income taxes
4,685
11.9%
185
0.5%
Provision for income taxes
1,529
3.9%
65
0.2%
Net income
3,156
8.0%
120
0.3%
Net Sales
Net sales finished at $39,230 for the three-month
period ended June 30, 2023, an increase of $5,739 or 17.1% versus prior year. The net sales increase was primarily driven by higher volumes
of our branded drinkable kefir, and to a lesser extent the impact of price increases implemented during the fourth quarter of 2022.
Net sales by product category were as follows for
the three months ended June 30:
2023
2022
$
%
$
%
Drinkable Kefir excluding ProBugs
$ 31,339
80%
$ 26,120
78%
Cheese
3,376
9%
2,998
9%
Drinkable yogurt
1,659
4%
1,526
5%
Cream and other
1,631
4%
1,596
5%
ProBugs Kefir
862
2%
817
2%
Other dairy
363
1%
434
1%
Net Sales
$ 39,230
100%
$ 33,491
100%
22
Gross Profit
Gross profit as a percentage of net sales was
28.7% during the three-month period ended June 30, 2023. Gross profit percentage was 17.0% in the prior year. The increase versus the
prior year was primarily due to the higher volumes of our branded products and the favorable impact of milk pricing, and to a lesser extent
the price increases implemented during the fourth quarter of 2022 and decreased transportation costs.
Selling Expenses
Selling expenses increased by $89 to $2,571 during
the three-month period ended June 30, 2023 from $2,482 during the same period in 2022.
General and Administrative Expenses
General and administrative expenses increased $969
to $3,808 during the three-month period ended June 30, 2023 from $2,839 during the same period in 2022. The increase is primarily driven
by incentive compensation and to a lesser extent expenses related to non-routine stockholder action.
Provision for Income Taxes
The provision for income taxes was $1,529 and $65
during the three months ended June 30, 2023 and 2022, respectively.
The effective income tax rate for the three months
ended June 30, 2023 was 32.6% compared to 35.3% in the same period last year. The statutory Federal and state tax rates remained consistent
from 2022 to 2023. The Company has items that are nondeductible or are discrete adjustments to tax expense. The Company consistently reflects
non-deductible officer compensation expense, non-deductible compensation expense related to equity incentive awards and separate state
tax rates from period to period. Although similar items were reflected in 2023, the percentage effect is different due to the difference
in pre-tax income in 2023 compared to 2022.
The Company’s effective tax rate may change
from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional
mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement
of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete
income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.
Income taxes are discussed in Note 10 in the Notes
to the Consolidated Financial Statements.
23
Six Months Ended June 30, 2023 Compared to Six Months Ended June
30, 2022
The following table presents certain information
concerning our financial results, including information presented as a percentage of consolidated net sales:
Six Months Ended June 30,
2023
2022
$
%
$
%
Net sales
77,134
100.0%
67,590
100.0%
Cost of goods sold
56,329
73.0%
55,070
81.5%
Depreciation expense
1,299
1.7%
1,243
1.8%
Total cost of goods sold
57,628
74.7%
56,313
83.3%
Gross profit
19,506
25.3%
11,277
16.7%
Selling expenses
6,090
7.9%
5,684
8.4%
General & administrative expense
6,943
9.0%
6,131
9.1%
Amortization expense
270
0.4%
270
0.4%
Total operating expenses
13,303
17.3%
12,085
17.9%
Income (loss) from operations
6,203
8.0%
(808 )
(1.2% )
Other (expense) income:
Interest expense
(213 )
(0.3% )
(94 )
(0.1% )
Gain on sales of property and equipment
33
0.0%
–
0.0%
Other (expense) income, net
–
0.0%
(5 )
0.0%
Total other (expense) income
(180 )
(0.3% )
(99 )
(0.1% )
Income (loss) before provision for income taxes
6,023
7.7%
(907 )
(1.3% )
Provision (benefit) for income taxes
2,037
2.6%
(132 )
(0.2% )
Net income (loss)
3,986
5.1%
(775 )
(1.1% )
Net Sales
Net sales finished at $77,134 for the six-month period
ended June 30, 2023, an increase of $9,544 or 14.1% versus prior year. The net sales increase was primarily driven by higher volumes of
our branded drinkable kefir, and to a lesser extent the impact of price increases implemented during the fourth quarter of 2022.
Net sales by product category were as follows
for the six months ended June 30:
2023
2022
$
%
$
%
Drinkable Kefir excluding ProBugs
$ 61,139
79%
$ 52,482
78%
Cheese
6,721
9%
6,022
9%
Cream and other
3,551
5%
3,564
5%
Drinkable yogurt
3,275
4%
3,077
5%
ProBugs Kefir
1,670
2%
1,599
2%
Other dairy
778
1%
846
1%
Net Sales
$ 77,134
100%
$ 67,590
100%
24
Gross Profit
Gross profit as a percentage of net sales was
25.3% during the six-month period ended June 30, 2023. Gross profit percentage was 16.7% in the prior year. The increase versus the prior
year was primarily due to the higher volumes of our branded products and the favorable impact of milk pricing, and to a lesser extent
the price increases implemented during the fourth quarter of 2022 and decreased transportation costs.
Selling Expenses
Selling expenses increased by $406 to $6,090 during
the six-month period ended June 30, 2023 from $5,684 during the same period in 2022. The increase is primarily due to increased compensation
expense, partially offset by the reduction in royalty expense resulting from the termination of the endorsement agreement in September
2022.
General and Administrative Expenses
General and administrative expenses increased $812
to $6,943 during the six-month period ended June 30, 2023 from $6,131 during the same period in 2022. The increase is primarily driven
by incentive compensation and to a lesser extent expenses related to non-routine stockholder action.
Provision (Benefit) for Income Taxes
The provision (benefit) for income taxes was $2,037
and $(132) during the six months ended June 30, 2023 and 2022, respectively.
The effective income tax rate for the six months ended
June 30, 2023 was 33.8% compared to 14.5% in the same period last year. The statutory Federal and state tax rates remained consistent
from 2022 to 2023. The Company has items that are nondeductible or are discrete adjustments to tax expense. The Company consistently reflects
non-deductible officer compensation expense, non-deductible compensation expense related to equity incentive awards and separate state
tax rates from period to period. Although similar items were reflected in 2023, the percentage effect is different due to the difference
in pre-tax (loss) income in 2023 compared to 2022.
The Company’s effective tax rate may change
from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional
mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement
of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete
income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.
Income taxes are discussed in Note 10 in the Notes
to the Consolidated Financial Statements.
Liquidity and Capital Resources
Management
assesses the Company's liquidity in terms of its ability to generate cash to fund its operating, investing, and financing activities.
The Company remains in a strong financial position, and while it has been impacted by the macroeconomic challenges with commodity inflation
and other input cost increases, the Company believes that its cash flow from operations, revolving credit and term loan facility, and
cash and cash equivalents will continue to provide sufficient liquidity for its working capital needs, capital resource requirements,
and growth initiatives and to ensure the continuation of the Company as a going concern.
25
If additional
borrowings are needed, $2,223 was available under the Revolving Credit Facility as of June 30, 2023 (see Note 7, Debt). We are in compliance
with the terms of the Credit Agreement and expect to meet foreseeable financial requirements. The success of our business and financing
strategies will continue to provide us with the financial flexibility to take advantage of various opportunities as they arise. To date,
we have been successful in generating cash and obtaining financing as needed. However, in connection with the COVID-19 pandemic or other
circumstances, if a serious economic or credit market crisis ensues, it could have a negative effect on our liquidity, results of operations
and financial condition.
The Company’s most significant
ongoing short-term cash requirements relate primarily to funding operations (including expenditures for raw materials, labor, manufacturing
and distribution, trade and promotions, advertising and marketing, and income tax liabilities) as well as expenditures for property, plant
and equipment.
Long-term cash
requirements primarily relate to funding long-term debt repayments (see Note 7, Debt) and deferred income taxes (see Note 10, Income Taxes,
in our Annual Report on Form 10-K).
Cash Flow
The following table is derived from our Consolidated
Statement of Cash Flows:
Six months Ended
June 30,
Net Cash Flows Provided By (Used In):
2023
2022
Operating activities
$ 5,455
$ (529 )
Investing activities
$ (1,950 )
$ (1,710 )
Financing activities
$ (500 )
$ (500 )
Operating Activities
Net cash provided by operating activities was $5,455
during the six-month period ended June 30, 2023 compared to net cashed used of $529 in the same period in 2022. The increase was primarily
due to higher cash earnings driven by increased product volumes and declines in certain input costs, and the change in working capital.
Investing Activities
Net cash used in investing activities was $1,950 during
the six-month period ended June 30, 2023 compared to $1,710 in the same period in 2022. The increase in cash used reflects our planned
capital spending increase during 2023 compared to 2022. Our capital spending is focused in three core areas: growth, cost reduction, and
facility improvements. Growth capital spending supports new product innovation and enhancements. Cost reduction and facility improvements
support manufacturing efficiency, safety, and productivity.
Financing Activities
Net cash used in financing activities was $500 during
the six-month period ended June 30, 2023 and 2022. The cash used represents the quarterly principal payments under the term loan.
26
Debt Obligations
As of June 30, 2023, the Company had $2,777 outstanding
and $2,223 available for future borrowings under the revolving line of credit. Under the Credit Agreement, the Revolving Credit facility
matures on June 30, 2025. The were no letters of credit issued or outstanding as of June 30, 2023. The Company had $3,230 outstanding
under the note payable, net of $20 of unamortized deferred financing fees, as of June 30, 2023.
The Company’s interest rate on debt outstanding
under the revolving line of credit and note payable as of June 30, 2023 was 7.14% and 7.10%, respectively.
The Company is in compliance with all applicable
financial debt covenants as of June 30, 2023. See Note 7 to our Consolidated Financial Statements for additional information regarding
our indebtedness and related agreements.
Recent Accounting Pronouncements
Information regarding recent accounting pronouncements
is provided in Note 2 – Summary of Significant Accounting Policies.
Critical Accounting Policies and Estimates
A description of the Company's critical accounting
policies and estimates is contained in its Annual Report on Form 10-K for the year ended December 31, 2022. There were no material changes
to the Company’s critical accounting policies and estimates in the six months ended June 30, 2023.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Not applicable.
ITEM 4. CONTROLS AND PROCEDURES.
Evaluation of Disclosure
Controls and Procedures
The Company has established
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange
Act”)) that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange
Commission (“SEC”), and such information is accumulated and communicated to management, including our Chief Executive Officer
(“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosure.
Management, together with our CEO and CFO, evaluated the effectiveness of the Company’s disclosure controls and procedures as of June
30, 2023. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of June
30, 2023.
Changes in Internal
Control over Financial Reporting
There have been no changes
in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during
the quarter ended June 30, 2023 that has materially affected or are reasonably likely to materially affect, our internal control
over financial reporting.
27
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
Information regarding legal preceding is available
in Note 9, Commitment and Contingencies.
ITEM 1A. RISK FACTORS.
There have been no material changes from the risk
factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 5. OTHER INFORMATION.
None.
ITEM 6. EXHIBITS.
No.
Description
Form
Period Ending
Exhibit
Filing Date
10.1
Early Opt-in Election and Related Amendment to Loan Documents
Filed Herewith
31.1
Rule 13a-14(a)/15d-14(a) Certification of Julie Smolyansky
Filed Herewith
31.2
Rule 13a-14(a)/15d-14(a) Certification of Eric Hanson
Filed Herewith
32.1
Section 1350 Certification of Julie Smolyansky *
Furnished Herewith
32.2
Section 1350 Certification of Eric Hanson *
Furnished Herewith
99.1
Press release dated August 14, 2023 reporting Lifeway’s financial results for the three months ended June 30, 2023*
Furnished Herewith
101.INS
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH
Inline XBRL Taxonomy Extension Schema Document
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).
* The
exhibits deemed furnished with this Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or
otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities
Act or the Exchange Act., whether made before or after the date of the filing of this Form 10-Q and irrespective of any general incorporation
language contained in such filing.
28
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
LIFEWAY FOODS, INC.
Date: August 14, 2023
By:
/s/ Julie Smolyansky
Julie Smolyansky
Chief Executive Officer, President, and Director
(Principal Executive Officer)
Date: August 14, 2023
By:
/s/ Eric Hanson
Eric Hanson
Chief Financial & Accounting Officer
(Principal Financial and Accounting Officer)
29
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.